Skip to content

The Role of Gastroesophageal Reflux in Scleroderma Pulmonary Fibrosis

Investigation Into the Role of Gastroesophageal Reflux in Pulmonary Fibrosis in Scleroderma

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02136394
Enrollment
100
Registered
2014-05-13
Start date
2014-02-28
Completion date
2017-04-30
Last updated
2016-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastroesophageal Reflux, Interstitial Lung Disease, Systemic Sclerosis

Brief summary

Scarring of the lungs is common in patients with scleroderma and is one of the main causes of death. Patients with scleroderma very frequently have problems with their gullet (esophagus), the food pipe that leads into the stomach. Normally, a small circular muscle at the base of the esophagus opens to allow food to pass into the stomach and closes to keep the digestive fluids from flowing back up into the gullet. In patients with scleroderma, the muscle may become weak and no longer close properly. Gastroesophageal reflux (GER) is the medical term for reflux of stomach contents into the esophagus. Our hypothesis is that small amounts of GER can move back up into the esophagus and get inhaled into the lungs, and may be one of the triggers for lung scarring. We propose to look for certain substances normally only found in the stomach in the exhaled breath condensate which is collected by breathing comfortably into a cooled cylinder, allowing the breath to condensate. In a smaller group of patients, we also plan to perform a bronchoalveolar lavage, a more widely studied test in which a small amount of fluid is introduced into a small part of the lungs through a fine tube, and then removed for examination, to evaluate whether the two tests provide similar measurements. We will also evaluate the correlation between these molecules and other tests, including lung function, and markers of lung scarring activity, and tests to look at how the esophagus is working so that we can get a clearer picture of how this affects patients' daily lives. Finally, we will be following up patients over time with lung function to see whether evidence of GER into the lungs is linked with a greater likelihood of worsening of lung scarring in the future.

Interventions

OTHERGastro-esophageal reflux

This is an observational study. The exposure is the gastro-esophageal reflux.

Sponsors

Royal Brompton & Harefield NHS Foundation Trust
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients aged \> 18 years * Diagnosis of SSc (American College of Rheumatology criteria) * Interstitial lung disease (\>5% extent of ILD on HRCT) * Only for bronchoscopy: presence of troublesome cough and/or GER symptoms and/or recurrent chest infections and/or asymmetry of ILD changes on CT

Exclusion criteria

* Significant communication difficulties * Unable to perform reliable lung function tests * Current smokers * Only for bronchoscopy: FEV1 less than 1L or DLCO less than 30% of the predicted

Design outcomes

Primary

MeasureTime frameDescription
Measurements of pepsin and pH in the Exhaled breath condensate (EBC)Baseline
In a subgroup pf 40 patients, measurements of pepsin and bile salts in bronchoalveolar lavage (BAL)Baseline
Serum KL-6BaselineSerum KL-6 is a known marker of alveolar epithelial damage in SSc-ILD

Secondary

MeasureTime frameDescription
Changes from baseline in longitudinal lung function assessmentBaseline, month 6, month 12, month 18Spirometry with total lung capacity, diffusing capacity for CO

Countries

United Kingdom

Contacts

Primary ContactElisabetta Renzoni, MD
e.renzoni@imperial.ac.uk02073528121

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 4, 2026